References
- NCCN Proceedings. NCCN practice guidelines for the treatment of breast cancer. Oncology 1999, 13, 187–212.
- Styblo, T M.; Wood, W C. Adjuvant chemotherapy in the node—negative breast cancer patient. Surg. Clin. North Am. 1996, 76, 327–341. [PUBMED], [INFOTRIEVE]
- Eissa, S.; Labib, R.; Khalifa, A.; Swelam, N.; Khalil, F.; Megeid El-Shenawy, A. Regulators of apoptosis in human breast cancer. Clin. Biochem. 1999, 32, 321–326. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Meyer, J S.; Fahrner, M.; Daniel, F C. Pathology and behavior of small breast carcinomas. Sem. Diag. Pathol. 1999, 16, 257–268. [CSA]
- Rudolph, P.; Olsson, H.; Bonatz, G.; Ratjen, V.; Bolte, H.; Baldetorp, B.; Ferno, M.; Parwaresch, R.; Alm, P. Correlation between p53, c-erbB-2, and topoisomerase IIa expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J. Pathol. 1999, 187, 207–216. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gasparini, G.; Toi, M.; Gion, M.; Verderio, P.; Dittadi, R.; Hanatani, M.; Matsubara, I.; Vinante, O.; Bonoldi, E.; Boracchi, P.; Gatti, C.; Suzuki, H.; Tominaga, T. Prognostic significance of vascular endothelial growth factor in node-negative breast carcinoma. J. Natl. Cancer Inst. 1997, 89, 139–147. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Garrido, F.; Ruiz-Cabello; Cabrera, T.; Perez-Villar; Lopez-Botet, M.; Duggan-Keen, M.; Stern, P. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol. Today 1997, 82, 88–94.
- http://bris.ac.uk/pathandmicro/services/GAI/cytokine4.htm
- Daser, A.; Mitchison, H.; Mitchison, A.; Muller, B. Non-classical MHC genetics of immunological disease in man and mouse: the role of pro-inflammatory cytokines. Cytokine 1996, 8, 593–597. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Turner, D.; Grant, S C.D.; Yonan, N.; Sheldon, S.; Dyer, P A.; Sinnott, P J.; Hutchinson, I V. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997, 64, 776–779. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hutchinson, I V.; Turner, D M.; Sankaran, D.; Awad, M R.; Sinnott, P J. Influence of cytokine genotypes on allograft rejection. Transplant. Proc. 1998, 30, 862–863. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Middleton, P G.; Taylor, P R.A.; Jackson, G.; Proctor, S J.; Dickinson, A M. Cytokine gene polymorphisms associating with severe graft versus host disease in HLA identical sibling transplants. Blood 1998, 92, 3943–3948. [PUBMED], [INFOTRIEVE], [CSA]
- Cavet, J.; Dickinson, A.; Norden, J.; Taylor, P R.A.; Jackson, G H.; Middleton, P G. Interferon g and interleukin-6 gene polymorphisms associate with graft-versus–host disease in HLA-matched sibling bone marrow transplantation. Blood 2001, 98, 1594–1600. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kuninaka, S.; Yano, T.; Yokoyama, H.; Fukuyama, Y.; Terazaki, Y.; Uehara, T.; Kanematsu, T.; Asoh, H.; Ichinose, Y. Direct influences of pro-inflammatory cytokines (IL-1b, TNF-a, IL-6) on the proliferation and cell surface antigen expression of cancer cells. Cytokine 2000, 12, 8–11. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ballen, K.; Hicks, J.; Dharan; Ambruso, D.; Anderson, K.; Bianco, C.; Bermiller, L.; Dickey, W.; Lottenberg, R.; O'Neill, M.; Popocsky, M.; Skerrett, D.; Sniecinski, I.; Wingard, J. Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion 2002, 42, 1279–1284., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Couchane, L.; Ahmed, S B.; Baccouche, S.; Remadi, S. Polymorphism in the tumor necrosis factor a promoter region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997, 80, 1489–1496. [CROSSREF]
- Fleiss, J L. Determining sample sizes needed to detect a difference between two proportions. In Statistical Methods for Rates and Proportions, 2nd Ed.; Fleiss, J L. Wiley Series in Probability and Mathematical Statistics: New York, 1981; 33–49.
- Densem, C G.; Hutchinson, I V.; Cooper, A.; Yonan, N.; Brooks, N H. Polymorphism of the transforming growth factor beta-1 gene correlates with the development of coronary vasculopathy following cardiac transplantation. J. Heart Lung Transplant. 2000, 19, 551–556. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sankaran, D.; Asderakis, A.; Ashraf, S.; Roberts, I S.D.; Short, C D.; Dyer, P A.; Sinnott, P J.; Hutchinson, I A. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int. 1999, 56, 281–288. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zheng, C.; Huang, D R.; Bergenbrant, S.; Sundblad, A.; Osterborg, A.; Bjorkholm, M.; Holm, G.; Yi, Q. Interleukin-6, tumor necrosis factor-a, interleukin-1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br. J. Hematol. 2000, 109, 39–45. [CROSSREF]
- Pravica, V.; Asderakis, A.; Perry, C.; Hajeer, A.; Sinnott, P J.; Hutchinson, I V. In vitro production of IFN-g correlates with CA repeat polymorphisms in the human IFN-gamma gene. Eur. J. Immunogenet. 1998, 26, 1–3. [CSA], [CROSSREF]
- Derynck, R.; Choy, L. Transforming growth factor-beta and its receptors. In The Cytokine Handbook; Thompson, A., Ed.; Academic Press: , CA, 1998.
- Ziv, E.; Cauley, J.; Morin, P A.; Saiz, R.; Browner, W S. Association between T29-C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women. JAMA 2001, 285, 2859–2863. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Xie, W.; Mertens, J C.; Reiss, D J.; Rimm, D L.; Camp, R L.; Reiss, M. Alerations of smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002, 62, 497–505. [PUBMED], [INFOTRIEVE]
- Reiss, M.; Barcellos-Hoff, M H. Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res. Treat. 1997, 45, 81–95. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Barcellos-Hoff, M H.; Brooks, A L. Extracellular sugnaling through the microenvironment: a hypothesis relating carcinogenesis, bystander effects, and genomic instability. Radiat. Res. 2001, 156, 618–627. [PUBMED], [INFOTRIEVE]
- Grainger, D J.; Heathcote, K.; Chiano, M.; Snieder, H.; Kemp, P R.; Metcalfe, J C.; Carter, N D.; Spector, T D. Genetic control of the circulating concentration of transforming growth factor type beat 1. Hum. Mol. Genet. 1999, 8, 93–97. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tang, B.; Bottinger, E P.; Jakowlew, S B.; , et al. Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 1998, 4, 802–807. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yang, Y A.; Dukhanina, O.; Tang, B.; Mamura, M.; Letterio, J J.; MacGregor, J.; Patel, S C.; Khozin, S.; Liu, Z Y.; Green, J.; Anver, M R.; Merlino, G.; Wakefield, L M. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse effects. J. Clin. Invest. 2002, 109, 1607–1615. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Tang, B.; de Castro, K.; Barnes, H E.; Tony Parks, W.; Stewart, L.; Bottinger, E P.; Danielpour, D.; Wakefield, L M. Loss of responsiveness to transforming growth factor beta induces malignant transformation or nontumorigenic rat prostate epithelial cells. Cancer Res. 1999, 59, 4832–4834.
- Gorelick, L.; Flavell, R A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat. Med. 2001, 7, 1118–1122. [CSA], [CROSSREF]
- Cui, W.; Kemp, C J.; Duffie, E.; Balmain, A.; Akhurst, R J. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53 null mice is prognostic for a high risk of malignant conversion. Cancer Res. 1994, 54, 5831–5836. [PUBMED], [INFOTRIEVE]